Secondary prophylaxis with rFVIIa in hemophilia and inhibitors: recommendations from an experts committee from Argentina.
Secondary prophylaxis with rFVIIa has been the subject of several publications in the past few years. However, there is no general consensus on how this treatment should be put into practice, as publications have been very heterogeneous in the dosing schedule they report. Furthermore, the mechanism of action of rFVIIa and its short half life have been used as arguments against its role in prophylaxis. There have been a series of recent publications that show that rFVIIa can traffic through the intact endothelium and be stored in the subendothelium of several organs for a prolonged period of time. In order to consensuate the role of rFVIIa in prophylaxis, a group of experts from Argentina, resumed available information regarding pharmacology and clinical experience with this treatment, and developed a series of recommendations to use this drug in the prophylaxis setting.
Pérez Bianco
Raúl
R
Instituto de Investigaciones Hematológicas Mariano R. Castex, Academia Nacional de Medicina, Buenos Aires, Argentina. perezbianco@hematologia.anm.edu.ar
Neme
Daniela
D
Candela
Miguel
M
Tezanos Pinto
Miguel de
Md
D001118:Argentina; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood*; D003029:Coagulants / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D015942:Factor VIIa / Q000008:administration & dosage*; D006467:Hemophilia A / Q000517:prevention & control*; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000008:administration & dosage; D016896:Treatment Outcome
D019774:Blood Coagulation Factor Inhibitors; D003029:Coagulants; D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa